J&J Vision names new president of its global surgery division

Tom Frinzi
Outgoing President Tom Frinzi previously led Abbott Medical Optics before it was acquired by J&J in 2016. (Photo: J&J)

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year, following a 35-year career in ophthalmology.

Frinzi previously led Abbott Medical Optics, including its cataract lens replacement, laser refractive surgery and consumer eye health businesses, before they were acquired by J&J for $4.325 billion in 2016.

He has been succeeded by Warren Foust, who most recently served as worldwide president of J&J’s aesthetics and plastic surgery company, Mentor, a standalone unit housed within the conglomerate’s Ethicon medical devices division. Foust was also a member of J&J’s Cardiovascular and Specialty Services Leadership Team.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“When thinking about who would be the next leader of the surgical vision business, I knew we needed a leader with a track record of success in leading global healthcare businesses, a people-centered leadership style, a keen appreciation for the customer experience, and a high touch approach to seeking customer partnership and input,” said Frinzi, who before joining Abbott, served as president and CEO of WaveTec Vision and held a variety of roles at Bausch & Lomb Surgical, Refractec and J&J.

RELATED: J&J Vision nets FDA approval for wavefront-guided PRK laser eye surgery

“Warren Foust exemplifies all of these traits, he’s a beloved leader at Johnson & Johnson, and this organization is in great hands with Warren at the helm,” he added.

Warren Foust (J&J)

Foust first joined J&J in 2011, through its acquisition of the orthopedics manufacturer Synthes. There he spent more than a decade in roles spanning trauma, joint reconstruction and craniofacial devices, as well as capital power equipment. Before that, he spent time pharmaceutical sales with Roche and Aventis.

RELATED: J&J launches new intraocular lens for cataract patients in Europe

“My priority on my first few days on the job will be to engage, listen and learn from our employees, our customers and our industry stakeholders,” Foust said in a statement. “I’ll be visiting every region in my first 100 days on the job, connecting directly with the ophthalmology community at industry events, customer meetings and Johnson & Johnson Vision’s annual kick-off meetings across APAC, EMEA and North and South America.”

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.